Home > Articles > Published articles > Consumption of caffeinated beverages and kidney function decline in an elderly Mediterranean population with metabolic syndrome |
Date: | 2021 |
Abstract: | It remains unclear whether caffeinated beverages could have deleterious renal effects in elderly population with underlying comorbid conditions. We investigated the associations between coffee, tea, or caffeine intake and 1-year changes in glomerular filtration rate (eGFR) in a large Spanish cohort of overweight/obese elderly with metabolic syndrome (MetS). This prospective analysis includes 5851 overweight/obese adults (55-75 years) with MetS from the PREDIMED-Plus study. We assessed coffee, tea, and caffeine consumption from a validated food-frequency questionnaire and creatinine-based eGFR using the Chronic Kidney Disease Epidemiology Collaboration equation. Multivariate-adjusted regression models were applied to test associations between baseline coffee, tea, or caffeine intake and 1-year eGFR changes. Caffeinated coffee (> 2 cups/day) and tea (at least 1 cup/day) drinkers had 0. 88 and 0. 93 mL/min/1. 73 m 2 greater eGFR decrease respectively, compared to those with less than 1 cup/day of coffee consumption or non-tea drinkers. Furthermore, caffeinated coffee consumption of > 2 cups/day was associated with 1. 19-fold increased risk of rapid eGFR decline > 3 mL/min/1. 73 m 2 (95% CI 1. 01-1. 41). Similarly, individuals in the highest (median, 51. 2 mg/day) tertile of caffeine intake had a 0. 87 mL/min/1. 73 m 2 greater eGFR decrease. Decaffeinated coffee was not associated with eGFR changes. In conclusion, higher consumption of caffeinated coffee, tea, and caffeine was associated with a greater 1-year eGFR decline in overweight/obese adults with MetS. |
Grants: | Ministerio de Educación, Política Social y Deporte FPU17/01925 Instituto de Salud Carlos III PI13/00673 Instituto de Salud Carlos III PI13/00492 Instituto de Salud Carlos III PI13/00272 Instituto de Salud Carlos III PI13/01123 Instituto de Salud Carlos III PI13/00462 Instituto de Salud Carlos III PI13/00233 Instituto de Salud Carlos III PI13/02184 Instituto de Salud Carlos III PI13/00728 Instituto de Salud Carlos III PI13/01090 Instituto de Salud Carlos III PI13/01056 Instituto de Salud Carlos III PI14/01722 Instituto de Salud Carlos III PI14/00636 Instituto de Salud Carlos III PI14/00618 Instituto de Salud Carlos III PI14/00696 Instituto de Salud Carlos III PI14/01206 Instituto de Salud Carlos III PI14/01919 Instituto de Salud Carlos III PI14/00853 Instituto de Salud Carlos III PI14/01374 Instituto de Salud Carlos III PI14/00972 Instituto de Salud Carlos III PI14/00728 Instituto de Salud Carlos III PI14/01471 Instituto de Salud Carlos III PI17/00764 Instituto de Salud Carlos III PI17/01183 Instituto de Salud Carlos III PI17/00855 Instituto de Salud Carlos III PI17/01347 Instituto de Salud Carlos III PI17/00525 Instituto de Salud Carlos III PI17/01827 Instituto de Salud Carlos III PI17/00532 Instituto de Salud Carlos III PI17/00215 Instituto de Salud Carlos III PI17/01441 Instituto de Salud Carlos III PI17/00508 Instituto de Salud Carlos III PI17/01732 Instituto de Salud Carlos III PI17/00926 European Commission 340918 "la Caixa" Foundation 2013ACUP00194 |
Note: | Altres ajuts: PROMETEO/2017/017 grant from the Generalitat Valenciana ; IISPV research projects 2019-2021 (Ref.: 2019/IISPV/03 grant to AD-L) |
Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Language: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Subject: | Nephrology ; Risk factors |
Published in: | Scientific reports, Vol. 11 (april 2021) , ISSN 2045-2322 |
13 p, 1.4 MB |